{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:06:38Z","timestamp":1773813998732,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,10,1]]},"DOI":"10.1093\/ndt\/16.10.1965","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T22:42:32Z","timestamp":1027723352000},"page":"1965-1967","source":"Crossref","is-referenced-by-count":25,"title":["Vitamin D analogues: how do they differ and what is their clinical role?"],"prefix":"10.1093","volume":"16","author":[{"given":"Simon J.","family":"Steddon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil J.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2001,10]]},"reference":[{"key":"key\n\t\t\t\t20180110090203_R1","doi-asserted-by":"crossref","unstructured":"Brown AJ. Vitamin D analogues. Am J Kidney Dis1998; 32: S25\u2013S39","DOI":"10.1053\/ajkd.1998.v32.pm9808141"},{"key":"key\n\t\t\t\t20180110090203_R2","unstructured":"Haussler MR, Haussler CA, Jurutka PW et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol1997; 154 [Suppl]: S57\u2013S73"},{"key":"key\n\t\t\t\t20180110090203_R3","doi-asserted-by":"crossref","unstructured":"Nykjaer A, Dragun D, Walther D et al. An endocytic pathway essential for renal uptake and activation of the steroid 25\u2010(OH) vitamin D3. Cell1999; 96: 507\u2013515","DOI":"10.1016\/S0092-8674(00)80655-8"},{"key":"key\n\t\t\t\t20180110090203_R4","doi-asserted-by":"crossref","unstructured":"Darwish HM, DeLuca HF. Analysis of binding of the 1,25\u2010dihydroxyvitamin D3 receptor to positive and negative vitamin D response elements. Arch Biochem Biophys1996; 334: 223\u2013234","DOI":"10.1006\/abbi.1996.0450"},{"key":"key\n\t\t\t\t20180110090203_R5","doi-asserted-by":"crossref","unstructured":"Baran DT, Quail JM, Ray R, Leszyk J, Honeyman T. Annexin II is the membrane receptor that mediates the rapid actions of 1 alpha,25\u2010dihydroxyvitamin D3. J Cell Biochem2000; 78: 34\u201346","DOI":"10.1002\/(SICI)1097-4644(20000701)78:1<34::AID-JCB4>3.0.CO;2-Z"},{"key":"key\n\t\t\t\t20180110090203_R6","doi-asserted-by":"crossref","unstructured":"Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol1999; 277: F157\u2013F175","DOI":"10.1152\/ajprenal.1999.277.2.F157"},{"key":"key\n\t\t\t\t20180110090203_R7","doi-asserted-by":"crossref","unstructured":"Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl1999; 73: S14\u2013S19","DOI":"10.1046\/j.1523-1755.1999.07304.x"},{"key":"key\n\t\t\t\t20180110090203_R8","doi-asserted-by":"crossref","unstructured":"Cunningham J. What is the optimal regimen for vitamin D? Kidney Int Suppl1999; 73: S59\u2013S64","DOI":"10.1046\/j.1523-1755.1999.07307.x"},{"key":"key\n\t\t\t\t20180110090203_R9","doi-asserted-by":"crossref","unstructured":"Malluche HH, Langub MC, Monier\u2010Faugere MC. Pathogenesis and histology of renal osteodystrophy. Osteoporos Int1997; 7: S184\u2013S187","DOI":"10.1007\/BF03194369"},{"key":"key\n\t\t\t\t20180110090203_R10","doi-asserted-by":"crossref","unstructured":"Norman AW. Receptors for 1alpha,25(OH)2D3: past, present and future. J Bone Miner Res1998; 13: 1360\u20131369","DOI":"10.1359\/jbmr.1998.13.9.1360"},{"key":"key\n\t\t\t\t20180110090203_R11","doi-asserted-by":"crossref","unstructured":"Brown AJ, Ritter CR, Finch JL et al. The noncalcemic analogue of vitamin D, 22\u2010oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest1989; 84: 728\u2013732","DOI":"10.1172\/JCI114229"},{"key":"key\n\t\t\t\t20180110090203_R12","doi-asserted-by":"crossref","unstructured":"Brown AJ, Finch J, Grieff M et al. The mechanism for the disparate actions of calcitriol and 22\u2010oxacalcitriol in the intestine. Endocrinology1993; 133: 1158\u20131164","DOI":"10.1210\/endo.133.3.8396012"},{"key":"key\n\t\t\t\t20180110090203_R13","doi-asserted-by":"crossref","unstructured":"Slatopolsky E, Finch J, Ritter C et al. A new analog of calcitriol, 19\u2010nor\u20101,25\u2010(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis1995; 26: 852\u2013860","DOI":"10.1016\/0272-6386(95)90455-7"},{"key":"key\n\t\t\t\t20180110090203_R14","doi-asserted-by":"crossref","unstructured":"Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E. A new analog of 1,25\u2010(OH)2D3, 19\u2010NOR\u20101,25\u2010(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis1997; 30: 105\u2013112","DOI":"10.1016\/S0272-6386(97)90571-0"},{"key":"key\n\t\t\t\t20180110090203_R15","doi-asserted-by":"crossref","unstructured":"Finch JL, Brown AJ, Slatopolsky E. Differential effects of 1,25\u2010dihydroxy\u2010vitamin D3 and 19\u2010nor\u20101,25\u2010dihydroxy\u2010vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol1999; 10: 980\u2013985","DOI":"10.1681\/ASN.V105980"},{"key":"key\n\t\t\t\t20180110090203_R16","doi-asserted-by":"crossref","unstructured":"Brown AJ, Finch J, Takahashi F, Slatopolsky E. Calcemic activity of 19\u2010nor\u20101,25(OH)2D2 decreases with duration of treatment. J Am Soc Nephrol2000; 11: 2088\u20132094","DOI":"10.1681\/ASN.V11112088"},{"key":"key\n\t\t\t\t20180110090203_R17","doi-asserted-by":"crossref","unstructured":"Knutson JC, LeVan LW, Valliere CR, Bishop CW. Pharmacokinetics and systemic effect on calcium homeostasis of 1alpha,24\u2010dihydroxyvitamin D2 in rats. Comparison with 1alpha,25\u2010dihydroxyvitamin D2, calcitriol, and calcipotriol. Biochem Pharmacol1997; 53: 829\u2013837","DOI":"10.1016\/S0006-2952(97)00004-X"},{"key":"key\n\t\t\t\t20180110090203_R18","doi-asserted-by":"crossref","unstructured":"McIntyre CW, Schroeder NJ, Burrin JM, Cunningham J. Effects of new analogues of vitamin D on bone cells: implications for treatment of uremic bone disease. Kidney Int1999; 55: 500\u2013511","DOI":"10.1046\/j.1523-1755.1999.00289.x"},{"key":"key\n\t\t\t\t20180110090203_R19","doi-asserted-by":"crossref","unstructured":"Goodman WG, Goldin J, Kuizon BD et al. Coronary\u2010artery calcification in young adults with end\u2010stage renal disease who are undergoing dialysis. N Engl J Med2000; 342: 1478\u20131483","DOI":"10.1056\/NEJM200005183422003"},{"key":"key\n\t\t\t\t20180110090203_R20","doi-asserted-by":"crossref","unstructured":"Kurokawa K, Akizawa T, Suzuki M, Akiba T, Ogata E, Slatopolsky E. Effect of 22\u2010oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study. Nephrol Dial Transplant1996; 11: 121\u2013124","DOI":"10.1093\/ndt\/11.supp3.121"},{"key":"key\n\t\t\t\t20180110090203_R21","doi-asserted-by":"crossref","unstructured":"Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y. Effect of 22\u2010oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis2000; 35: 458\u2013464","DOI":"10.1016\/S0272-6386(00)70198-3"},{"key":"key\n\t\t\t\t20180110090203_R22","doi-asserted-by":"crossref","unstructured":"Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19\u2010Nor\u20101\u2010alpha\u201025\u2010dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol1998; 9: 1427\u20131432","DOI":"10.1681\/ASN.V981427"},{"key":"key\n\t\t\t\t20180110090203_R23","doi-asserted-by":"crossref","unstructured":"Tan AU, Jr, Levine BS, Mazess RB et al. Effective suppression of parathyroid hormone by 1alpha\u2010hydroxy\u2010vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int1997; 51: 317\u2013323","DOI":"10.1038\/ki.1997.39"},{"key":"key\n\t\t\t\t20180110090203_R24","doi-asserted-by":"crossref","unstructured":"Frazao JM, Elangovan L, Maung HM et al. Intermittent doxercalciferol (1alpha\u2010hydroxyvitamin D2) therapy for secondary hyperparathyroidism. Am J Kidney Dis2000; 36: 550\u2013561","DOI":"10.1053\/ajkd.2000.16193"},{"key":"key\n\t\t\t\t20180110090203_R25","doi-asserted-by":"crossref","unstructured":"Akiba T, Marumo F, Owada A et al. Controlled trial of falecalcitriol versus alfacalcidol in supression of parathyroid hormone in haemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis1998; 32: 238\u2013246","DOI":"10.1053\/ajkd.1998.v32.pm9708607"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/16\/10\/1965\/23369308\/161965.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T16:53:40Z","timestamp":1621270420000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/16\/10\/1965\/1866118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,1]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2001,10]]},"published-print":{"date-parts":[[2001,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/16.10.1965","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2001,10]]},"published":{"date-parts":[[2001,10,1]]}}}